Foghorn Therapeutics Reports Q3 2025 Financial Results
I'm PortAI, I can summarize articles.
Foghorn Therapeutics, Inc. (FHTX) reported its Q3 2025 financial results, showing a net loss of $15.8 million, an improvement from $19.1 million last year. The company generated $8.2 million in collaboration revenue, mainly from its partnership with Eli Lilly. Operating expenses decreased to $26.7 million, driven by lower research and development costs. Cash and cash equivalents rose to $89.3 million, with total assets at $205 million. Foghorn plans to continue investing in R&D while pursuing long-term growth despite expected ongoing losses.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments